Looking at tumor response to erlotinib or gefitinib, Mellinghoff et al. [15] found that EGFRvIII sensitize tumors to EGFR kinase inhibitors, and loss of the phosphotase tensin homologue of ten (PTEN) tumor suppressor would impair the response to such inhibitors. The gene discussed is EGFR; the disease is neoplasm.